Research programme: rheumatoid arthritis gene therapies - MeiraGTx Netherlands
Alternative Names: ART-D01; ART-G01; ART-T01; ART-T02; rAAV5.interferon-β.stufferLatest Information Update: 29 Jun 2022
At a glance
- Originator Arthrogen
- Developer MeiraGTx Netherlands
- Class Gene therapies
- Mechanism of Action Chemokine inhibitors; Gene transference; Immunomodulators; Inflammation mediator inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Netherlands (Intra-articular)
- 17 Jan 2011 Preclinical development is ongoing Netherlands
- 13 Jun 2009 Pharmacokinetics data from a preclinical trial in rheumatoid arthritis presented at the 10th Annual Congress of the European League Against Rheumatism (EULAR-2009)